Patents Assigned to MiNK Therapeutics, Inc.
  • T CELL RECEPTORS THAT BIND TO NY-ESO-1 AND METHODS OF USE THEREOF
    Publication number: 20240102044
    Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
    Type: Application
    Filed: March 27, 2023
    Publication date: March 28, 2024
    Applicant: MiNK Therapeutics, Inc.
    Inventors: Marc van Dijk, Volker Seibert, Cornelia Anne Mundt, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf, Daniel Leventhal, Sébastien Lalevée, Reed Masakayan
  • Engineered host cells and methods of use thereof
    Patent number: 11898165
    Abstract: Provided herein are engineered host cells suitable for expression of functional T cell receptors (TCR) and methods of using these cells to identify TCRs that specifically bind to a desired peptide-major histocompatibility complex (MHC) complex.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: February 13, 2024
    Assignee: MiNK Therapeutics, Inc.
    Inventors: Marc Van Dijk, Volker Seibert, Robert Benjamin Stein
  • T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
    Patent number: 11718658
    Abstract: Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: August 8, 2023
    Assignee: MiNK Therapeutics, Inc.
    Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Alessandra Franchino, Sébastien Lalevée, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf
  • T cell receptors that bind to NY-ESO-1 and methods of use thereof
    Patent number: 11613764
    Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: March 28, 2023
    Assignee: MiNK Therapeutics, Inc.
    Inventors: Marc van Dijk, Volker Seibert, Cornelia Anne Mundt, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf, Daniel Leventhal, Sébastien Lalevée, Reed Masakayan